OncoMark is a diagnostics company focused on the development of novel panels of cancer biomarkers to aid treatment decisions and allow more tailored patient management, ultimately improving the quality of life for cancer patients.
OncoMark was acquired in March 2021 by another company. The company intends to commercialize OncoMark’s lead product, the OncoMasTR assay in the next 6-12 months. OncoMasTR is a novel prognostic test for early stage breast cancer. This gene expression profiling test accurately estimates the risk of disease recurrence for patients, thereby aiding clinical decision-making for improved treatment strategies.
The development of OncoMasTR utilized the OncoMasTR Technology, which identifies upstream drivers of cancer progression. This technology has the potential to be applied in other human cancers where significant unmet needs also exist. Indeed, the founding staff of OncoMark will be using the OncoMasTR technology at OncoAssure, a new Irish diagnostics company, to explore the development of panels of cancer biomarkers for applications in prostate cancer and other cancers.